Pamiparib, a novel PARP 1/2 inhibitor, monotherapy for gBRCAm patients with recurrent ovarian, fallopian, and primary peritoneal cancer: An open-label, multicenter, phase II trial in China | |
Wu, X.; Wang, J.; Zhou, Q.; Gu, T.; Zhang, K.; Liang, J.; Mu, S.; Ge, R.; Yang, H.; Huang, V. | |
2018 | |
卷号 | 29 |
会议录 | ANNALS OF ONCOLOGY |
语种 | 英语 |
URL标识 | 查看原文 |
ISSN号 | 0923-7534 |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3607870 |
专题 | 复旦大学上海医学院 |
推荐引用方式 GB/T 7714 | Wu, X.,Wang, J.,Zhou, Q.,et al. Pamiparib, a novel PARP 1/2 inhibitor, monotherapy for gBRCAm patients with recurrent ovarian, fallopian, and primary peritoneal cancer: An open-label, multicenter, phase II trial in China[C]. 见:. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论